The agency explained that the treatment, which is marketed under the name “Likembe”, has become recommended for patients Alzheimer’s Who have not yet reached an advanced stage of the disease.
A statement issued by the European Medicines Agency said: “After reviewing its preliminary opinion, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended granting marketing authorization for the drug Lekimbi (lecanimab) for the treatment of mild cognitive impairment (speech, memory and thinking disorders) or mild dementia due to Alzheimer’s disease.” This is for certain groups of patients.
The statement added: “The review concluded that the benefits outweigh the risks in a limited number of patients.”
In July, she ruled European Medicines Agency Against the marketing of “Likembe” in European Unionconsidering that the observed effect of the treatment is not compared to the risks of serious side effects, including possible bleeding in the brain.
But the agency approved the treatment on Thursday only for patients at lower risk of a possible brain hemorrhage.
The drug “Likembe”, developed by the Japanese pharmaceutical laboratory “Eisai” and the American manufacturer “Biogen”, was licensed in January 2023 in US For patients who have not reached an advanced stage of the disease, it is also marketed in Japan And China.
Despite decades of research, scientists have so far failed to achieve a real breakthrough in treating Alzheimer’s disease, which affects tens of millions of people around the world, especially since the exact cause of this disease is still not well understood.
